Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetaben PET Imaging for Beta-amyloid Detection
NCT01020838Phase 3Completed
- Sponsor
- Life Molecular Imaging
- Start
- Nov 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of florbetaben in Alzheimer's disease (AD), sponsored by Life Molecular Imaging. Primary endpoint: Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem Specimens. Started Nov 2009; status: completed.
02
Drugs
florbetaben
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01020838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01020838.